← All Recursion Pharmaceuticals, INC filings

Recursion Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
RXRX
Recursion Pharmaceuticals, INC
10-K: Recursion Pharmaceuticals 2025 10-K: AI-Native Drug Discovery Advances
Recursion Pharmaceuticals reports significant progress in 2025, achieving its first AI-enabled clinical proof of concept and advancing a diversified pipeline through its integrated AI-native drug discovery and development platform.
NASDAQ
RXRX
Recursion Pharmaceuticals, INC
10-K: Recursion Pharmaceuticals' 2024 10-K Filing: AI-Driven Drug Discovery Takes Center Stage
Recursion Pharmaceuticals highlights its AI-driven drug discovery advancements, clinical milestones, and strategic partnerships in its 2024 10-K filing, emphasizing its commitment to decoding biology to radically improve lives.
NASDAQ
RXRX
Recursion Pharmaceuticals, INC
10-K: Recursion Pharmaceuticals 10-K Filing: Decoding Biology for Drug Discovery
Recursion Pharmaceuticals' 10-K filing highlights its progress in TechBio, emphasizing its AI-driven drug discovery platform, clinical pipeline advancements, and strategic collaborations.